Scientific Posters , Pediatrics , Drug Product Optimization

EuPFI 2021: Taste Assessment Study of Belumosudil to Inform an Integrated Pediatric Formulation Development Program

30 October 2021
Overview

Presented at the 2021 EuPFI event, the poster documents the project of a ROCK2 selective inhibitor in development for the treatment of immune disorders.

Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders. An oral suspension formulation is being investigated as a possible pediatric formulation for patients aged between three months and twelve years. This study aimed to select and identify a suitable, novel belumosudil oral suspension formulation, with an optimal flavor and/or sweetener combination to improve palatability in the target population.

The study comprises a taste assessment and relative bioavailability in a two-part protocol. The initial study part (Part 1) involves a ‘sip and spit’ taste assessment to profile the taste characteristics of the API and identify a suitable flavor system which can be taken into Part 2 for a relative bioavailability assessment of the novel oral suspension compared to the reference adult oral tablet formulation.

Download
Date
30 October 2021
Ask The Experts

Pediatric drug development questions? Get answers from our team.

Have a question about your pediatric drug program? Ask a member of our team about our capabilities for drug product clinical manufacturing, commercial manufacturing, or clinical testing to keep your pediatric drug program on-track.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Nazim Kanji

Executive Director, Pediatric Services

Nazim Kanji has over 25 years of experience in the pharmaceutical and consumer healthcare industries, where he has worked in produ...

About Nazim
Dr. Asma Patel

VP, Integrated Development Services

Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...

About Asma
Get in touch
Humanity can't afford to wait, so neither can we.